Eligibility for Intramuscular Cabotegravir/Rilpivirine in HIV-Positive Patients: An Observational Study

<b>Background:</b> HIV treatment has advanced significantly with the introduction of simpler antiretroviral regimens, but adherence remains a challenge. In this context, the long-acting injectable combination cabotegravir/rilpivirine (CAB/RPV) emerges as a promising alternative to improve adherence and quality of life for patients. <b>Objective</b>: The purpose of this study was to determine the proportion of patients with HIV-1 on antiretroviral therapy (ART) who meet the criteria for the use of intramuscular CAB/RPV. <b>Methods</b>: A single-center, retrospective observational study was conducted on patients with HIV-1 receiving ART at a Spanish hospital. Adult patients with at least 6 months of stable ART and a viral load result in the previous 12 months were included. Pregnant women, patients with less than 6 months of ART, or those without a recent viral load were excluded. The primary endpoint was the proportion of patients meeting the criteria for intramuscular CAB/RPV: undetectable viral load, stable ART, adherence >90%, no resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs)/integrase strand transfer inhibitors (INSTIs), no enzyme inducers, no anticoagulants, and no hepatitis B virus (HBV) infection. We also measure the risk of virological failure. Costs and treatment complexity were analyzed. <b>Results</b>: A total of 194 patients were included. In total, 68% met the criteria for intramuscular CAB/RPV. The main reasons for ineligibility were a recent ART switch (16%) and lack of adherence (11.3%). The mean annual incremental cost per patient when switching to CAB/RPV was €651.51. <b>Conclusion and Relevance</b>: A considerable proportion of patients with HIV meet the criteria for intramuscular CAB/RPV. However, lack of adherence and the costs associated with intramuscular therapy represent barriers to its implementation. Strategies to improve adherence and cost-effectiveness studies are needed.

Authors

Institutions

Publication Details

Journal
Journal of Pharmacy Technology
Published
2025-05-08
DOI
https://doi.org/10.1177/87551225251333698
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Eligibility for Intramuscular Cabotegravir/Rilpivirine in HIV-Positive Patients: An Observational Study

Francisco José Rodríguez Lucena, Gabriel Martínez-Orea, Elena Arroyo‐Domingo, Francisca Fuentes-Hidalgo et al.
Journal of Pharmacy Technology
HIV/AIDS Research and Interventions
article

Eligibility for Intramuscular Cabotegravir/Rilpivirine in HIV-Positive Patients: An Observational Study

Francisco José Rodríguez Lucena, Gabriel Martínez-Orea, Elena Arroyo‐Domingo, Francisca Fuentes-Hidalgo, José Manuel del-Moral-Sánchez, Agustina Ruiz-Gómez
article en

Abstract

<b>Background:</b> HIV treatment has advanced significantly with the introduction of simpler antiretroviral regimens, but adherence remains a challenge. In this context, the long-acting injectable combination cabotegravir/rilpivirine (CAB/RPV) emerges as a promising alternative to improve adherence and quality of life for patients. <b>Objective</b>: The purpose of this study was to determine the proportion of patients with HIV-1 on antiretroviral therapy (ART) who meet the criteria for the use of intramuscular CAB/RPV. <b>Methods</b>: A single-center, retrospective observational study was conducted on patients with HIV-1 receiving ART at a Spanish hospital. Adult patients with at least 6 months of stable ART and a viral load result in the previous 12 months were included. Pregnant women, patients with less than 6 months of ART, or those without a recent viral load were excluded. The primary endpoint was the proportion of patients meeting the criteria for intramuscular CAB/RPV: undetectable viral load, stable ART, adherence >90%, no resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs)/integrase strand transfer inhibitors (INSTIs), no enzyme inducers, no anticoagulants, and no hepatitis B virus (HBV) infection. We also measure the risk of virological failure. Costs and treatment complexity were analyzed. <b>Results</b>: A total of 194 patients were included. In total, 68% met the criteria for intramuscular CAB/RPV. The main reasons for ineligibility were a recent ART switch (16%) and lack of adherence (11.3%). The mean annual incremental cost per patient when switching to CAB/RPV was €651.51. <b>Conclusion and Relevance</b>: A considerable proportion of patients with HIV meet the criteria for intramuscular CAB/RPV. However, lack of adherence and the costs associated with intramuscular therapy represent barriers to its implementation. Strategies to improve adherence and cost-effectiveness studies are needed.

Journal of Pharmacy TechnologyVol. 41(4)
Hospital Vega Baja (ES)
Good health and well-being
Openalex Percentile: Top 87%
HIV/AIDS Research and Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.